301267 华厦眼科
已收盘 09-02 15:00:00
资讯
新帖
简况
9月1日增减持汇总:恒工精密等12股拟减持,华厦眼科拟增持(表)
新浪证券 · 09-01 22:15
9月1日增减持汇总:恒工精密等12股拟减持,华厦眼科拟增持(表)
华厦眼科最新公告:实控人拟增持不低于3000万元股份
证券之星 · 09-01 19:09
华厦眼科最新公告:实控人拟增持不低于3000万元股份
华厦眼科:实控人苏庆灿拟增持不低于3000万元
格隆汇 · 09-01 19:06
华厦眼科:实控人苏庆灿拟增持不低于3000万元
股市必读:华厦眼科中报 - 第二季度单季净利润同比下降9.06%
证券之星 · 08-31
股市必读:华厦眼科中报 - 第二季度单季净利润同比下降9.06%
华厦眼科(301267)披露2026年半年度报告,8月28日股价下跌5.03%
证券之星 · 08-28
华厦眼科(301267)披露2026年半年度报告,8月28日股价下跌5.03%
华厦眼科(301267)6月30日股东户数2.01万户,较上期减少5.38%
证券之星 · 08-28
华厦眼科(301267)6月30日股东户数2.01万户,较上期减少5.38%
股市必读:华厦眼科新发布《关于持股5%以上股东减持股份的预披露公告》
证券之星 · 08-28
股市必读:华厦眼科新发布《关于持股5%以上股东减持股份的预披露公告》
图解华厦眼科中报:第二季度单季净利润同比下降9.06%
证券之星 · 08-28
图解华厦眼科中报:第二季度单季净利润同比下降9.06%
华厦眼科:相关研发项目及科研成果转化尚在逐步探索和落地中
证券之星 · 08-21
华厦眼科:相关研发项目及科研成果转化尚在逐步探索和落地中
股市必读:华厦眼科(301267)8月12日董秘有最新回复
证券之星 · 08-13
股市必读:华厦眼科(301267)8月12日董秘有最新回复
华厦眼科:公司内部核查后未发现存在未授权使用情形
证券之星 · 08-12
华厦眼科:公司内部核查后未发现存在未授权使用情形
股市必读:华厦眼科(301267)8月7日董秘有最新回复
证券之星 · 08-10
股市必读:华厦眼科(301267)8月7日董秘有最新回复
华厦眼科:暂未涉及眼科创新药的自主研发
证券之星 · 08-07
华厦眼科:暂未涉及眼科创新药的自主研发
股市必读:华厦眼科(301267)7月3日董秘有最新回复
证券之星 · 07-06
股市必读:华厦眼科(301267)7月3日董秘有最新回复
华厦眼科:在高度近视、难治性青光眼、圆锥角膜、干眼诊疗、糖尿病视网膜病变等前沿领域均取得了系统性突破
证券之星 · 07-03
华厦眼科:在高度近视、难治性青光眼、圆锥角膜、干眼诊疗、糖尿病视网膜病变等前沿领域均取得了系统性突破
华厦眼科:积极通过多渠道开展沟通交流传递公司价值
证券之星 · 07-03
华厦眼科:积极通过多渠道开展沟通交流传递公司价值
华厦眼科(301267)披露2025年年度权益分派实施公告,6月29日股价上涨3.88%
证券之星 · 06-29
华厦眼科(301267)披露2025年年度权益分派实施公告,6月29日股价上涨3.88%
【私募调研记录】富安基金调研华厦眼科
证券之星 · 06-15
【私募调研记录】富安基金调研华厦眼科
华厦眼科涨5.68%,东吴证券一个月前给出“买入”评级
证券之星 · 06-12
华厦眼科涨5.68%,东吴证券一个月前给出“买入”评级
东海证券:给予华厦眼科买入评级
证券之星 · 05-31
东海证券:给予华厦眼科买入评级
加载更多
公司概况
公司名称:
华厦眼科医院集团股份有限公司
所属行业:
卫生
上市日期:
2022-11-07
主营业务:
华厦眼科医院集团股份有限公司的主营业务是眼科医疗服务。公司的主要产品是白内障专科、屈光专科、眼底病专科、斜弱视与小儿眼科专科、眼表病专科、青光眼专科、眼眶与眼肿瘤专科、眼外伤专科、眼视光。公司下属医院厦门眼科中心是国家三级甲等专科医院、国家临床重点专科(眼科)建设单位,并设有博士后科研工作站和院士专家工作站。
发行价格:
50.88
{"stockData":{"symbol":"301267","market":"SZ","secType":"STK","nameCN":"华厦眼科","latestPrice":15.08,"timestamp":1788332598000,"preClose":15.21,"halted":0,"volume":3966646,"delay":0,"changeRate":-0.0085,"floatShares":648000000,"shares":840000000,"eps":0.5365,"marketStatus":"已收盘","change":-0.13,"latestTime":"09-02 15:00:00","open":15.22,"high":15.23,"low":15.05,"amount":59891400,"amplitude":0.0118,"askPrice":15.08,"askSize":35,"bidPrice":15.07,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.5365,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.21,"symbolType":"stock","openAndCloseTimeList":[[1788312600000,1788319800000],[1788325200000,1788332400000]],"highLimit":16.73,"lowLimit":13.69,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":840000000,"isCdr":false,"pbRate":2.36,"roa":"--","peRate":28.108108,"roe":"5.41%","epsLYR":0.53,"committee":0.488479,"marketValue":12667000000,"turnoverRate":0.0061,"status":1,"floatMarketCap":9779000000},"requestUrl":"/m/hq/s/301267","defaultTab":"news","newsList":[{"id":"2664185212","title":"9月1日增减持汇总:恒工精密等12股拟减持,华厦眼科拟增持(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664185212","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664185212?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:15","pubTimestamp":1788272100,"startTime":"0","endTime":"0","summary":"9月1日盘后,据不完全统计,包括怡亚通、恒工精密、维宏股份、九州一轨、中曼石油、上海洗霸、拱东医疗、今创集团、东北制药、金域医学、永臻股份、富春染织在内的12家A股上市公司披露拟减持情况,华厦眼科披露拟增持情况。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-01/doc-iniqitrs1600522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301261","BK0236","BK0259","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664316855","title":"华厦眼科最新公告:实控人拟增持不低于3000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2664316855","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664316855?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:09","pubTimestamp":1788260959,"startTime":"0","endTime":"0","summary":"华厦眼科(301267.SZ)公告称,公司实际控制人、董事长兼总经理苏庆灿计划自公告披露之日起3个月内,通过集中竞价方式增持公司股份,计划增持金额不低于3000万元。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100036027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853053","title":"华厦眼科:实控人苏庆灿拟增持不低于3000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853053","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664853053?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:06","pubTimestamp":1788260813,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663047482","title":"股市必读:华厦眼科中报 - 第二季度单季净利润同比下降9.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663047482","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663047482?lang=zh_cn&edition=full","pubTime":"2026-08-31 05:53","pubTimestamp":1788126792,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,华厦眼科报收于15.3元,下跌5.03%,换手率1.68%,成交量10.9万手,成交额1.67亿元。业绩披露要点:2026年中报显示归母净利润2.92亿元,同比增长3.55%;但第二季度扣非净利润同比下降22.47%。交易信息汇总资金流向8月28日主力资金净流入882.23万元,占总成交额5.28%;游资资金净流入2127.9万元,占总成交额12.74%;散户资金净流出3010.13万元,占总成交额18.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064117","title":"华厦眼科(301267)披露2026年半年度报告,8月28日股价下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064117","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662064117?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:46","pubTimestamp":1787914010,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,华厦眼科报收于15.3元,较前一交易日下跌5.03%,最新总市值为128.52亿元。该股当日开盘15.71元,最高15.8元,最低15.2元,成交额达1.67亿元,换手率为1.68%。华厦眼科于2026年8月28日披露《2026年半年度报告摘要》。报告期内,公司实现营业收入2,185,227,265.04元,较上年同期增长2.17%;归属于上市公司股东的净利润为291,961,802.70元,同比增长3.55%;扣除非经常性损益后的净利润为260,960,250.69元,同比下降6.08%。经营活动产生的现金流量净额为480,659,702.91元,同比增长13.40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069376","title":"华厦眼科(301267)6月30日股东户数2.01万户,较上期减少5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069376","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662069376?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:57","pubTimestamp":1787911026,"startTime":"0","endTime":"0","summary":"证券之星消息,近日华厦眼科披露,截至2026年6月30日公司股东户数为2.01万户,较3月31日减少1144.0户,减幅为5.38%。在医疗服务行业个股中,华厦眼科股东户数低于行业平均水平,截至6月30日,医疗服务行业平均股东户数为4.76万户。从股价来看,2026年3月31日至2026年6月30日,华厦眼科区间跌幅为13.46%,在此期间股东户数减少1144.0户,减幅为5.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662317840","title":"股市必读:华厦眼科新发布《关于持股5%以上股东减持股份的预披露公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662317840","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662317840?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:39","pubTimestamp":1787873953,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘,华厦眼科报收于16.11元,下跌0.49%,换手率0.58%,成交量3.76万手,成交额6016.88万元。公司公告汇总:2026年半年度报告显示,公司实现营业收入21.85亿元,同比增长2.17%;归母净利润2.92亿元,同比增长3.55%;扣非净利润2.61亿元,同比下降6.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800013924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662087096","title":"图解华厦眼科中报:第二季度单季净利润同比下降9.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662087096","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662087096?lang=zh_cn&edition=full","pubTime":"2026-08-28 03:02","pubTimestamp":1787857369,"startTime":"0","endTime":"0","summary":"证券之星消息,华厦眼科2026年中报显示,上半年度公司主营收入21.85亿元,同比上升2.17%;归母净利润2.92亿元,同比上升3.55%;扣非净利润2.61亿元,同比下降6.08%;其中2026年第二季度,公司单季度主营收入10.35亿元,同比下降1.02%;单季度归母净利润1.2亿元,同比下降9.06%;单季度扣非净利润1.07亿元,同比下降22.47%;负债率28.07%,投资收益-285.79万元,财务费用2473.3万元,毛利率44.12%。财报数据概要请见下图:本文数据来源于华厦眼科2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800006195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661553182","title":"华厦眼科:相关研发项目及科研成果转化尚在逐步探索和落地中","url":"https://stock-news.laohu8.com/highlight/detail?id=2661553182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661553182?lang=zh_cn&edition=full","pubTime":"2026-08-21 08:57","pubTimestamp":1787273827,"startTime":"0","endTime":"0","summary":"证券之星消息,华厦眼科08月20日在投资者关系平台上答复投资者关心的问题。目前相关研发项目及科研成果转化尚在逐步探索和落地中,存在不确定性,对公司业绩不构成重大影响,敬请投资者注意投资风险。再次感谢您对华厦眼科的支持!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100009125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659904385","title":"股市必读:华厦眼科(301267)8月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659904385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659904385?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:38","pubTimestamp":1786556293,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,华厦眼科报收于16.45元,下跌0.66%,换手率0.59%,成交量3.81万手,成交额6308.07万元。公司始终重视知识产权保护,已建立并将持续完善知识产权合规审核机制,防范此类风险。再次感谢您对华厦眼科的支持!当日关注点交易信息汇总:8月12日主力资金净流出410.45万元,占总成交额6.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658776978","title":"华厦眼科:公司内部核查后未发现存在未授权使用情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2658776978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658776978?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:09","pubTimestamp":1786525744,"startTime":"0","endTime":"0","summary":"证券之星消息,华厦眼科08月12日在投资者关系平台上答复投资者关心的问题。您所提及的相关情况,公司内部核查后未发现存在未授权使用情形,未收到包含具体侵权证据的沟通文件,亦未收到该事项相关的诉讼或仲裁文书,不知您的信息从何而来?公司始终重视知识产权保护,已建立并将持续完善知识产权合规审核机制,防范此类风险。再次感谢您对华厦眼科的支持!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200028676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658707346","title":"股市必读:华厦眼科(301267)8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658707346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658707346?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:45","pubTimestamp":1786297514,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,华厦眼科报收于16.15元,上涨1.25%,换手率1.12%,成交量7.27万手,成交额1.16亿元。董秘最新回复投资者: 您好,请问公司有没有眼科创新药?再次感谢您对华厦眼科的支持!当日关注点交易信息汇总:8月7日主力资金净流出772.71万元,占总成交额6.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657169018","title":"华厦眼科:暂未涉及眼科创新药的自主研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2657169018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657169018?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:06","pubTimestamp":1786086380,"startTime":"0","endTime":"0","summary":"证券之星消息,华厦眼科(301267)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,请问公司有没有眼科创新药?另请问公司AI眼镜合作开发进展如何?华厦眼科回复:尊敬的投资者您好,感谢您对华厦眼科的关注。公司始终专注于眼科医疗服务主业,目前暂未涉及眼科创新药的自主研发,智能眼镜相关应用尚在逐步探索和落地中,存在不确定性,对公司业绩不构成重大影响,敬请投资者注意投资风险。再次感谢您对华厦眼科的支持!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700020503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","BK1574","301267","159992","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649161925","title":"股市必读:华厦眼科(301267)7月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649161925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649161925?lang=zh_cn&edition=full","pubTime":"2026-07-06 04:33","pubTimestamp":1783283590,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,华厦眼科报收于15.14元,上涨1.88%,换手率0.73%,成交量4.72万手,成交额7102.07万元。2025年,公司新增专利授权35项,新增发表科研文章267篇,其中SCI收录178篇;新增获批医学科研项目46项;新增开展各类临床试验项目21项并担任PI;新增参与制定或修订的行业标准27项。再次感谢您对华厦眼科的支持!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600001596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648659840","title":"华厦眼科:在高度近视、难治性青光眼、圆锥角膜、干眼诊疗、糖尿病视网膜病变等前沿领域均取得了系统性突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2648659840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648659840?lang=zh_cn&edition=full","pubTime":"2026-07-03 15:06","pubTimestamp":1783062377,"startTime":"0","endTime":"0","summary":"证券之星消息,华厦眼科07月03日在投资者关系平台上答复投资者关心的问题。目前公司相关科研成果转化及智能技术应用尚在逐步探索和落地中,存在不确定性,对公司业绩不构成重大影响,敬请投资者注意投资风险。再次感谢您对华厦眼科的支持!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300022201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648810658","title":"华厦眼科:积极通过多渠道开展沟通交流传递公司价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2648810658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648810658?lang=zh_cn&edition=full","pubTime":"2026-07-03 11:36","pubTimestamp":1783049782,"startTime":"0","endTime":"0","summary":"证券之星消息,华厦眼科07月02日在投资者关系平台上答复投资者关心的问题。公司始终密切关注资本市场动态,高度重视股东权益,积极通过组织召开业绩交流会、现场集中调研、接待投资者来访、参加券商投资策略会、线上线下反路演等多渠道、多形式,开展广泛的沟通交流,传递公司价值,听取投资者对公司发展的意见及建议。再次感谢您对华厦眼科的支持!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300018182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647713320","title":"华厦眼科(301267)披露2025年年度权益分派实施公告,6月29日股价上涨3.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647713320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647713320?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:53","pubTimestamp":1782726832,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘,华厦眼科报收于15.53元,较前一交易日上涨3.88%,最新总市值为130.45亿元。该股当日开盘15.03元,最高15.63元,最低14.68元,成交额达8226.14万元,换手率为0.83%。近日,公司发布《2025年年度权益分派实施公告》。本次权益分派股权登记日为2026年7月2日,除权除息日为2026年7月3日。公司回购专用证券账户中的股份不参与本次权益分派。现金红利由公司委托中国结算深圳分公司代派,部分股东由公司自行派发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900028332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301267","BK0236"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643223860","title":"【私募调研记录】富安基金调研华厦眼科","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643223860?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:01","pubTimestamp":1781481685,"startTime":"0","endTime":"0","summary":"根据市场公开信息及6月12日披露的机构调研信息,知名私募富安基金近期对1家上市公司进行了调研,相关名单如下:1)华厦眼科 (富安基金参与公司特定对象调研&现场参观)个股亮点:公司积极推进大数据、人工智能等新一代信息技术的应用,加速构建智慧医疗体系,持续提升诊疗服务水平。;公司已与部分智能眼镜生产企业合作,开展智能眼镜验配,进一步挖掘智能眼镜在眼科医疗服务领域的应用潜力。目前相关业务尚在逐步探索和落地中,对公司业绩不构成重大影响以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026061500000309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642266880","title":"华厦眼科涨5.68%,东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642266880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642266880?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:39","pubTimestamp":1781253576,"startTime":"0","endTime":"0","summary":"今日华厦眼科(301267)涨5.68%,收盘报16.57元。2026年4月29日,东吴证券研究员朱国广,冉胜男,苏丰发布了对华厦眼科的研报《2025年报&2026年一季度点评:26Q1业绩回暖,屈光业务引领增长》,该研报对华厦眼科给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为56.28%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为西部证券的吕晔。华厦眼科(301267)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","301267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639660773","title":"东海证券:给予华厦眼科买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639660773","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639660773?lang=zh_cn&edition=full","pubTime":"2026-05-31 14:35","pubTimestamp":1780209315,"startTime":"0","endTime":"0","summary":"东海证券杜永宏近期对华厦眼科进行研究并发布了研究报告《公司简评报告:业绩稳健增长,诊疗术式持续提升》,给予华厦眼科买入评级。报告期内,公司业绩整27.07%体稳健增长,盈利能力逐渐提升。 消费眼科增长良好,白内障业务降幅收窄。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家;过去90天内机构目标均价为23.87。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100003473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301267"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788391874324,"stockEarnings":[{"period":"1week","weight":-0.0686},{"period":"1month","weight":-0.091},{"period":"3month","weight":-0.0868},{"period":"6month","weight":-0.134},{"period":"1year","weight":-0.2507},{"period":"ytd","weight":-0.1518}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0346},{"period":"3month","weight":-0.0287},{"period":"6month","weight":-0.0443},{"period":"1year","weight":0.0216},{"period":"ytd","weight":-0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华厦眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"20129人(较上一季度减少5.38%)","perCapita":"32214股","listingDate":"2022-11-07","address":"福建省厦门市湖里区五通西路999号之1701","registeredCapital":"84000万元","survey":" 华厦眼科医院集团股份有限公司的主营业务是眼科医疗服务。公司的主要产品是白内障专科、屈光专科、眼底病专科、斜弱视与小儿眼科专科、眼表病专科、青光眼专科、眼眶与眼肿瘤专科、眼外伤专科、眼视光。公司下属医院厦门眼科中心是国家三级甲等专科医院、国家临床重点专科(眼科)建设单位,并设有博士后科研工作站和院士专家工作站。","listedPrice":50.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华厦眼科(301267)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华厦眼科(301267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华厦眼科,301267,华厦眼科股票,华厦眼科股票老虎,华厦眼科股票老虎国际,华厦眼科行情,华厦眼科股票行情,华厦眼科股价,华厦眼科股市,华厦眼科股票价格,华厦眼科股票交易,华厦眼科股票购买,华厦眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华厦眼科(301267)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华厦眼科(301267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}